EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DOT1L inhibition reprograms innate immunity to potentiate immunomodulatory drug responses in multiple myeloma

Kazuya Ishiguro, Hiroshi Kitajima, Takeshi Niinuma, Reo Maruyama, Tomohide Tsukahara, Yoshihiko Hirohashi, Akari Takaya, Kohei Kumegawa, Ayano Yoshido, Shohei Sekiguchi, Hajime Sasaki, Akira Yorozu und 5 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217941 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Kazuya Ishiguro und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Biology, Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo, Japan, S1, W17, Chuo-ku, Sapporo, …. Hauptthemen laut MEDLINE: Multiple Myeloma, Histone-Lysine N-Methyltransferase, Immunity, Innate, Lenalidomide. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Northern Advancement Center for Science and Technology, Princess Takamatsu Cancer Research Fund, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunomodulatory drugs (IMiDs), such as lenalidomide, are a cornerstone of multiple myeloma (MM) treatment; however, their efficacy remains suboptimal. We previously reported that inhibition of DOT1L, a histone H3 lysine 79 methyltransferase, upregulates interferon (IFN)-regulated genes (IRGs) and exerts anti-MM effects. In this study, we aimed to further elucidate the epigenetic dependency of DOT1L in MM and the mechanism by which its inhibition induces innate immune signaling. Analysis of DepMap portal data revealed that MM cells are preferentially dependent on DOT1L, among epigenetic regulators, for survival. DOT1L inhibition activated type I IFN responses and increased expression of human leukocyte antigen (HLA) class II genes in MM cells. Notably, DOT1L inhibition was associated with induction of DNA damage responses. CRISPR/Cas9-mediated knockout of STING1 attenuated IRG induction and diminished the anti-proliferative effects of DOT1L inhibition, suggesting that activation of STING signaling contributes to its anti-MM activity. Furthermore, DOT1L inhibition downregulated IKZF1/3 and IRF4, which was also associated with IRG induction. Finally, DOT1L inhibition enhanced the anti-MM efficacy of lenalidomide by further upregulating IRGs and suppressing IRF4-MYC signaling. These findings suggest that DOT1L is a preferential epigenetic therapeutic target in MM. Its inhibition not only activates innate immune signaling but also enhances the efficacy of lenalidomide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHistone-Lysine N-MethyltransferaseImmunity, InnateLenalidomideImmunomodulating AgentsHumansCell Line, TumorSignal TransductionEpigenesis, GeneticGene Expression Regulation, NeoplasticInterferon Regulatory FactorsMembrane ProteinsCell ProliferationInterferon Regulatory Factor-4STING Protein

Stichwörter der Autor:innen

EpigeneticsImmunomodulatory drugsInnate immune signalingMultiple myeloma

Substanzen

Histone-Lysine N-MethyltransferaseLenalidomideImmunomodulating AgentsInterferon Regulatory FactorsMembrane ProteinsInterferon Regulatory Factor-4DOT1L protein, humanSTING1 protein, humanSTING Protein

Autor:innen und Institutionen

  • Division of Molecular Biology, Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo, Japan, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan; Division of Gastroenterology and Hepatology, Departme…
  • Division of Molecular Biology, Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo, Japan, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.
  • Department of Cancer Epigenome, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan; Cancer Cell Diversity Project, Next-Ganken program, Japanese Foun…
  • Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan, S1, W17, Chuo-ku, Sapporo, 060-8556, Japan.
  • Cancer Cell Diversity Project, Next-Ganken program, Japanese Foundation for Cancer Research, Tokyo, Japan 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan, S1, W16, Chuo-ku, Sapporo, 060-8556, Japan.

Förderung

  • Northern Advancement Center for Science and Technology
  • Princess Takamatsu Cancer Research Fund
  • Japan Society for the Promotion of Science
  • Akiyama Life Science Foundation

Zitieren

APA

Ishiguro, K., Kitajima, H., Niinuma, T., Maruyama, R., Tsukahara, T., Hirohashi, Y., Takaya, A., Kumegawa, K., Yoshido, A., Sekiguchi, S., Sasaki, H., Yorozu, A., Toyota, M., Kai, M., Torigoe, T., Nakase, H., & Suzuki, H. (2025). DOT1L inhibition reprograms innate immunity to potentiate immunomodulatory drug responses in multiple myeloma. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217941

Vancouver

Ishiguro K, Kitajima H, Niinuma T, Maruyama R, Tsukahara T, Hirohashi Y, et al. DOT1L inhibition reprograms innate immunity to potentiate immunomodulatory drug responses in multiple myeloma. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217941

BibTeX
@article{Ishiguro2025,
  author = {Ishiguro, Kazuya and Kitajima, Hiroshi and Niinuma, Takeshi and Maruyama, Reo and Tsukahara, Tomohide and Hirohashi, Yoshihiko and Takaya, Akari and Kumegawa, Kohei and Yoshido, Ayano and Sekiguchi, Shohei and Sasaki, Hajime and Yorozu, Akira and Toyota, Mutsumi and Kai, Masahiro and Torigoe, Toshihiko and Nakase, Hiroshi and Suzuki, Hiromu},
  title = {DOT1L inhibition reprograms innate immunity to potentiate immunomodulatory drug responses in multiple myeloma},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217941}
}
Kostenlos starten →